Rémy Hanf

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

Vlad Ratziu, Stephen A. Harrison, Sven Francque et al. · Gastroenterology · 2016 · 1K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

Bart Staels, A. Rubenstrunk, Benoît Noël et al. · Hepatology · 2013 · 405 citations

Medicine, Pharmacology, Hepatology +15

A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study

Stephen Harrison, Vlad Ratziu, Jérôme Boursier et al. · ˜The œLancet. Gastroenterology & hepatology · 2020 · 243 citations

Medicine, Internal Medicine, Pathology +16

Dual Peroxisome Proliferator–Activated Receptor α/δ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects

Bertrand Cariou, Rémy Hanf, S. Lambert-Porcheron et al. · Diabetes Care · 2013 · 209 citations · Full text

Medicine, Endocrinology, Pharmacology +15

A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA

Jörn M. Schattenberg, Albert Parés, Kris V. Kowdley et al. · Journal of Hepatology · 2021 · 178 citations · Full text

Medicine, Internal Medicine, Pharmacology +8